보고서 요약(국문)

개요
전 세계 각막윤부 줄기세포 결핍증 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
각막윤부 줄기세포 결핍증(LSCD)은 눈의 각막윤부 줄기세포에 기능 장애나 손상이 발생한 질환입니다. 각막윤부 줄기세포는 각막의 건강과 완전성을 유지하는 데 중요한 역할을 합니다. 이 줄기세포는 각막의 가장 바깥층인 각막 상피를 재생하는 역할을 합니다.
각막윤부 줄기세포가 소실되면 각막 상피는 재생되거나 스스로 치유될 수 없습니다. 이는 각막 결막화 및 신생혈관 형성, 각막 흉터, 만성 염증, 상피 파괴 및 지속적인 상피 이상으로 이어집니다.
시장 동향
각막 질환으로 인한 실명 증가
각막 질환으로 인한 실명 증가는 시장 성장의 주요 동인입니다. 각막 실명은 각막 투명도를 변화시켜 각막 흉터와 실명을 유발하는 일련의 안과 질환을 말합니다. 전 세계적으로 600만 명 이상이 각막 실명으로 고통받고 있으며, 윤부 줄기세포 결핍이 주요 원인 중 하나입니다.
예를 들어, 세계보건기구(WHO)에 따르면 각막 혼탁으로 인한 실명은 190만 명으로, 전체 실명 환자의 약 5%를 차지합니다. 또한, 현재 전 세계적으로 약 130만 명이 각막 실명으로 고통받고 있으며, 820만 명이 속눈썹증(trichiasis)을 앓고 있는 것으로 추산됩니다.
더불어, 미국 안과학회(AAOP)의 2023년 자료에 따르면, 각막 혼탁으로 인해 40세 이상 인구 중 550만 명이 양쪽 눈 시력이 20/60보다 나빠진 것으로 추산되며, 620만 명이 추가로 한쪽 눈 실명을 겪을 것으로 예측됩니다.

또한, 각막윤부 줄기세포 결핍증에 대한 인식 증가와 치료법에 대한 임상 시험 증가와 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
치료 관련 합병증
통증, 시야 흐림, 감염 및 시력 손실 위험을 증가시키는 재발성 상피 미란은 치료받지 않은 각막윤부 줄기세포 결핍증(LSCD)의 증상입니다. 감염성 각막염은 흔한 합병증입니다. 후기 단계에서는 표층 및 심층 혈관 신생, 궤양, 용해 및 천공으로 이어지는 지속적인 상피 결손, 섬유혈관성 판누스, 흉터, 각질화 및 석회화가 발생할 수 있습니다.
세분화 분석
전 세계 각막윤부 줄기세포 결핍증 시장은 유형, 치료법, 최종 사용자 및 지역별로 세분화됩니다.
수술 부문은 시장 점유율의 약 56.7%를 차지했습니다.
각막윤부 줄기세포 결핍증 치료법에는 각막 조직의 재생을 촉진하는 각막 이식 및 윤부 이식이 포함될 수 있습니다. 단측 부분 각막윤부 줄기세포 결핍증(LSCD)은 각막 표면에서 결막 상피를 반복적으로 제거하는 순차적 부분 결막 상피 절제술(SSCE) 형태로 치료되어 왔습니다. 수술 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
예를 들어, Clinicaltrials.gov에 따르면, 2022년 10월 26일 S.N. Fyodorov 안과 미세수술 국립기관은 각막윤부 대체를 위한 입술 점막 상피 이식에 대한 임상 시험을 진행했습니다. 이 연구의 목적은 새로운 수술적 개입의 임상적 적용 가능성을 평가하는 것입니다. 연구 완료 예정일은 2025년 12월입니다.
또한, 2023년 1월 23일 퀘벡 대학병원-라발 대학교는 각막윤부 줄기세포 결핍증 치료를 위한 자가 배양 각막 상피(CECA)에 대한 임상 시험을 진행했습니다. 예상 임상 시험 완료일은 2025년 12월입니다.
지역 분석
북미는 전 세계 각막윤부 줄기세포 결핍증 시장 점유율에서 중요한 위치를 차지할 것으로 예상됩니다.
북미는 신약 승인 증가 및 의료비 지출 증가와 같은 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 2022년 4월 미국 식품의약국(FDA)은 지속성 각막 상피 결손 치료제인 KPI-012에 대해 신속 심사(Fast Track) 지정을 승인했습니다. KPI-012는 인간 중간엽 줄기세포 분비체(MSC-S) 플랫폼을 사용하여 설계된 국소 투여 안과 치료제입니다. KPI-012는 손상된 각막 치유를 개선하기 위해 인간 유래 생체 인자를 함유하고 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 각막윤부 줄기세포 결핍증 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 인해 광범위한 봉쇄와 제한 조치가 시행되었고, 이는 전 세계적으로 정기적인 진단, 치료, 신약 출시 및 상담에 영향을 미쳤습니다. 팬데믹 발생으로 인해 많은 제약 회사나 의료기기 제조업체는 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 출근하지 못하는 상황이 발생했습니다. 따라서 이러한 요인들로 인해 각막줄기세포 결핍증 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.
시장 세분화
유형별
• 선천성 LSCD
• 후천성 LSCD
치료법별
• 수술적 치료
o 순차적 부분 결막 상피 절제술(SSCE)
o 결막 윤부 자가이식(CLAU)
o 각막-윤부 동종이식(KLAL)
o 단순 윤부 상피 이식(SLET)
o 배양 윤부 상피 이식(CLET)
• 비수술적 치료
o 코르티코스테로이드 점안액
o 치료용 소프트 콘택트렌즈
o 안구 윤활제
o 자가혈청 점안액
최종 사용자별
• 병원
• 전문 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양 지역
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 기업으로는 Chiesi USA Inc., Holostem Terapie Avanzate S.r.l., Kala Pharmaceuticals, Sandoz Group AG, Xenon Pharmaceuticals Inc., Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., Abbvie Inc. 등이 있습니다.
주요 개발 사항
• 2023년 4월, Kala Pharmaceuticals의 자회사인 Combangio, Inc.는 캘리포니아 재생 의학 연구소(California Institute for Regenerative Medicine)로부터 지속성 각막 상피 결손 치료를 위한 KPI-012 프로그램 지원을 위해 1,500만 달러를 지원받았습니다.
보고서 구매 이유

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 윤부 줄기세포 결핍 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위해. • 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 각막줄기세포 결핍증 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 각막줄기세포 결핍증 시장 보고서는 약 61개의 표, 63개의 그림, 185페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Limbal Stem Cells Deficiency Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Limbal stem cell deficiency (LSCD) is a condition that occurs when there is dysfunction or damage to the limbal stem cells in the eye. Limbal stem cells play a crucial role in maintaining the health and integrity of the cornea. These stem cells are responsible for regenerating the corneal epithelium which is the outermost layer of the cornea.
The corneal epithelium cannot regenerate or heal itself if these stem cells are gone. This leads to corneal conjunctivalization and neovascularization, corneal scarring, chronic inflammation, epithelium breakdown, and persistent epithelial abnormalities.
Market Dynamics
The increasing burden of corneal blindness
The increasing burden of corneal blindness acts as a significant driver for market growth. Corneal blindness refers to a group of eye disorders that change the corneal transparency, causing corneal scarring and blindness. Over 6 million people worldwide are affected by corneal blindness, and limbal stem cell deficiency is one of the main causes.
For instance, according to the World Health Organization, 1.9 million people have corneal blindness due to the opacification of the cornea, which accounts for about 5% of the total patients who have blindness. Also, It is currently estimated that, globally, there are about 1.3 million people blind from the disease and a further 8.2 million have trichiasis.
Additionally, according to the American Academy of Opthalmology 2023, due to corneal opacities, it is estimated that 5.5 million people over 40 have bilateral vision loss worse than 20/60. It is predicted that 6.2 million more people are blind in one eye.
Furthermore, significant growth drivers such as the growing awareness of limbal stem cell deficiency, and increasing clinical trials for treatment therapies are expected to drive the market in the forecast period.
Complications associated with the treatment
The pain, blurred vision, and recurring epithelial erosions that increase the risk of infection and vision loss are all symptoms of untreated limbal stem cell deficiency (LSCD). Infectious keratitis is a common complication. In late stages, superficial and deep vascularization, persistent epithelial defects leading to ulceration, melting and perforation, fibrovascular pannus, scarring, keratinization, and calcification can occur.
Segment Analysis
The global limbal stem cell deficiency market is segmented based on type, treatment, end user and region.
The surgical segment accounted for approximately 56.7% of the market share
Treatments for limbal stem cell deficiency can include corneal transplant and limbal graft, which promote the regrowth of corneal tissue. Unilateral partial LSCD has been treated by repeated removal of the conjunctival epithelium from the corneal surface in the form of sequential sectoral conjunctival epitheliectomy (SSCE). The surgical segment is expected to hold the largest market share over the period forecast.
For instance, according to Clinicaltrials.gov, on October 26, 2022, the S.N. Fyodorov Eye Microsurgery State Institution conducted a clinical trial on Labial Mucosal Epithelium Grafting for Corneal Limbus Substitution. The purpose of the study is to evaluate the feasibility of the novel surgical intervention in clinical use. The expected study completion date is December 2025.
Additionally, on January 23, 2023, CHU de Quebec-Universite Laval conducted a clinical trial for Autologous Cultured Corneal Epithelium (CECA) for the treatment of Limbal Stem Cell Deficiency. The expected trial completion date is December 2025.
Geographical Analysis
North America is expected to hold a significant position in the global limbal stem cell deficiency market share
North America has maintained a significant market proportion due to factors such as the rising drug approval, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, in April 2022, The Food and Drug Administration (FDA) granted Fast Track designation to KPI-012 for the treatment of persistent corneal epithelial defect. KPI-012 is a topically dosed ophthalmic therapy designed using the human mesenchymal stem cell secretome (MSC-S) platform. KPI-012 contains human-derived biofactors to correct the impaired corneal healing.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global limbal stem cell deficiency market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the limbal stem cell deficiency market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• Congenital LSCD
• Acquired LSCD
By Treatment
• Surgical
o Sequential sector conjunctival epitheliectomy (SSCE)
o Conjunctival limbal autograft (CLAU)
o Kerato-limbal allograft (KLAL)
o Simple limbal epithelial transplantation (SLET)
o Cultivated limbal epithelial transplant (CLET)
• Non-surgical
o Corticosteroid Eye drops
o Therapeutic soft contact lens
o Eye lubrication
o Autologous serum drops
By End User
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Chiesi USA Inc., Holostem Terapie Avanzate S.r.l., Kala Pharmaceuticals, Sandoz Group AG, Xenon Pharmaceuticals Inc., Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., Abbvie Inc. among others.
Key Developments
• In April 2023, Combangio, Inc., a subsidiary of Kala Pharmaceuticals, was awarded $15 Million by the California Institute for Regenerative Medicine to support the ongoing KPI-012 Program for the treatment of the persistent corneal epithelial defect.
Why Purchase the Report?
• To visualize the global limbal stem cell deficiency market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of limbal stem cell deficiency market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global limbal stem cells deficiency market report would provide approximately 61 tables, 63 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing burden of corneal blindness
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Complications associated with the treatment
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Congenital LSCD*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Acquired LSCD
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Surgical*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Sequential sector conjunctival epitheliectomy (SSCE)
8.2.4. Conjunctival limbal autograft (CLAU)
8.2.5. Kerato-limbal allograft (KLAL)
8.2.6. Simple limbal epithelial transplantation (SLET)
8.2.7. Cultivated limbal epithelial transplant (CLET)
8.3. Non-surgical
8.3.1. Corticosteroid Eye drops
8.3.2. Therapeutic soft contact lens
8.3.3. Eye lubrication
8.3.4. Autologous serum drops
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Specialty Clinics
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Chiesi USA Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Holostem Terapie Avanzate S.r.l.
12.3. Kala Pharmaceuticals
12.4. Sandoz Group AG
12.5. Xenon Pharmaceuticals Inc
12.6. Bausch + Lomb Corp
12.7. Rayner Group
12.8. AdvaCare Pharma
12.9. Eyeris Vision Care Pvt. Ltd.
12.10. Abbvie Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Chiesi USA Inc., 4.	Key Developments, Holostem Terapie Avanzate S.r.l., Kala Pharmaceuticals, Sandoz Group AG, Xenon Pharmaceuticals Inc, Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., Abbvie Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Limbal Stem Cells Deficiency Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Limbal Stem Cells Deficiency Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Limbal Stem Cells Deficiency Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Limbal Stem Cells Deficiency Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Limbal Stem Cells Deficiency Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Limbal Stem Cells Deficiency Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Limbal Stem Cells Deficiency Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Limbal Stem Cells Deficiency Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Limbal Stem Cells Deficiency Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Limbal Stem Cells Deficiency Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 South America Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 20 South America Limbal Stem Cells Deficiency Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Limbal Stem Cells Deficiency Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Limbal Stem Cells Deficiency Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Limbal Stem Cells Deficiency Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Limbal Stem Cells Deficiency Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Limbal Stem Cells Deficiency Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Chiesi USA Inc.: Overview

Table 33 Chiesi USA Inc.: Product Portfolio

Table 34 Chiesi USA Inc.: Key Developments

Table 35 Holostem Terapie Avanzate S.r.l.: Overview

Table 36 Holostem Terapie Avanzate S.r.l.: Product Portfolio

Table 37 Holostem Terapie Avanzate S.r.l.: Key Developments

Table 38 Kala Pharmaceuticals: Overview

Table 39 Kala Pharmaceuticals: Product Portfolio

Table 40 Kala Pharmaceuticals: Key Developments

Table 41 Sandoz Group AG: Overview

Table 42 Sandoz Group AG: Product Portfolio

Table 43 Sandoz Group AG: Key Developments

Table 44 Xenon Pharmaceuticals Inc: Overview

Table 45 Xenon Pharmaceuticals Inc: Product Portfolio

Table 46 Xenon Pharmaceuticals Inc: Key Developments

Table 47 Bausch + Lomb Corp: Overview

Table 48 Bausch + Lomb Corp: Product Portfolio

Table 49 Bausch + Lomb Corp: Key Developments

Table 50 Rayner Group: Overview

Table 51 Rayner Group: Product Portfolio

Table 52 Rayner Group: Key Developments

Table 53 AdvaCare Pharma: Overview

Table 54 AdvaCare Pharma: Product Portfolio

Table 55 AdvaCare Pharma: Key Developments

Table 56 Eyeris Vision Care Pvt. Ltd.: Overview

Table 57 Eyeris Vision Care Pvt. Ltd.: Product Portfolio

Table 58 Eyeris Vision Care Pvt. Ltd.: Key Developments

Table 59 Abbvie Inc.: Overview

Table 60 Abbvie Inc.: Product Portfolio

Table 61 Abbvie Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 2 Global Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 4 Global Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 5 Global Limbal Stem Cells Deficiency Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Limbal Stem Cells Deficiency Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 7 Congenital LSCD Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 8 Acquired LSCD Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 9 Global Limbal Stem Cells Deficiency Market Y-o-Y Growth, By Treatment, 2022-2031 (%)

Figure 10 Surgical Treatment in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 11 Non-surgical Treatment in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 12 Global Limbal Stem Cells Deficiency Market Y-o-Y Growth, By End User, 2022-2031 (%)

Figure 13 Hospitals End User in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 14 Specialty Clinics End User in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 15 Others End User in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 16 End User in Global Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 17 Global Limbal Stem Cells Deficiency Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 18 North America Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 19 Asia-Pacific Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 20 Europe Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 21 South America Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 22 Middle East and Africa Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 23 North America Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 24 North America Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 25 North America Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 26 North America Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 27 North America Limbal Stem Cells Deficiency Market Share, By Country, 2022 & 2031 (%)

Figure 28 South America Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 29 South America Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 30 South America Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 31 South America Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 32 South America Limbal Stem Cells Deficiency Market Share, By Country, 2022 & 2031 (%)

Figure 33 Europe Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 34 Europe Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 35 Europe Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 36 Europe Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 37 Europe Limbal Stem Cells Deficiency Market Share, By Country, 2022 & 2031 (%)

Figure 38 Asia-Pacific Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 39 Asia-Pacific Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 40 Asia-Pacific Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 41 Asia-Pacific Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 42 Asia-Pacific Limbal Stem Cells Deficiency Market Share, By Country, 2022 & 2031 (%)

Figure 43 Middle East & Africa Limbal Stem Cells Deficiency Market Value, 2022-2031 (US$ Million)

Figure 44 Middle East & Africa Limbal Stem Cells Deficiency Market Share, By Type, 2022 & 2031 (%)

Figure 45 Middle East & Africa Limbal Stem Cells Deficiency Market Share, By Treatment, 2022 & 2031 (%)

Figure 46 Middle East & Africa Limbal Stem Cells Deficiency Market Share, By End User, 2022 & 2031 (%)

Figure 47 Chiesi USA Inc.: Financials

Figure 48 Holostem Terapie Avanzate S.r.l.: Financials

Figure 49 Kala Pharmaceuticals: Financials

Figure 50 Sandoz Group AG: Financials

Figure 51 Xenon Pharmaceuticals Inc: Financials

Figure 52 Bausch + Lomb Corp: Financials

Figure 53 Rayner Group: Financials

Figure 54 AdvaCare Pharma: Financials

Figure 55 Eyeris Vision Care Pvt. Ltd.: Financials

Figure 56 Abbvie Inc.: Financials

세계 각막윤부줄기세포결핍증 시장 – 2023-2030

Global Limbal Stem Cells Deficiency Market- 2023-2030